The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advancedBRAF V600-mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i

Category Primary study
JournalJournal of Clinical Oncology
Year 2019
This article has no abstract
Epistemonikos ID: ef51823d71e06f269a3f5807fb215f855f4dd8b4
First added on: Feb 11, 2025